TRIBE-UPDATED
Regimen
- Experimental
- FOLFOXIRI + bevacizumab
- Control
- FOLFIRI + bevacizumab
Population
Metastatic CRC, 1L, previously untreated; updated OS analysis with RAS/BRAF subgroup data (long-term follow-up), enriched for BRAF-mutant subgroup.
Key finding
1L mCRC updated OS: FOLFOXIRI+bev vs FOLFIRI+bev: mOS 29.8 vs 25.8 mo (HR 0.80, 95% CI 0.65-0.98, p=0.030); BRAF-mut subgroup: mOS 19.0 vs 10.7 mo (HR 0.54); RAS-wt subgroup: mOS 37.1 vs 29.6 mo; RAS-mut subgroup: mOS 22.6 vs 20.6 mo; PFS 12.3 vs 9.7 mo confirmed
Source: PMID 26338525
Timeline
Guideline citations
- NCCN Colon (p.59)
- NCCN Rectal (p.76)